Use of tPA is also approved up to 4.5 h post-stroke onset in the UK by the Medicines and Healthcare Products Regulatory Agency, and recommended up to 4.5 h by AHA and ASA [15]. The gene discussed is PLAT; the disease is stroke disorder.